Biologic drugs remain inaccessible to most patients in emerging markets. Biosimilars represent a compelling proposition for patient affordability and access, and attractive value for governments in many of these countries. However, quality concerns, technology hurdles, lack of robust regulatory frameworks, and development timelines and costs

中文翻译：

---

市场观察：新兴市场中生物仿制药的策略

新兴市场上的大多数患者仍然无法获得生物药物。生物仿制药代表了许多患者负担能力和可及性的诱人主张，并且对许多国家的政府而言具有诱人的价值。但是，质量问题，技术障碍，缺乏健全的监管框架以及开发时间表和成本不足